MedTech Dive January 10, 2024
CEO Robert Ford is “very confident” in Abbott’s ability to pass $10 billion in sales of its Libre continuous glucose monitor products by 2028.
Abbott CEO Robert Ford expects the company to meet its goal of $10 billion in sales for its Libre diabetes devices by 2028.
“We feel very, very confident in our ability to deliver that $10 billion by 2028. I’d like to go beyond that,” Ford told investors at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday.
Abbott’s Freestyle Libre continuous glucose monitors have been a top performer for the company, bringing in $4.3 billion in sales in 2022, a 22% increase year over year. To meet its goal, Abbott needs to maintain a...
Today's Sponsors
Today's Sponsor